Development of Integrated Multimodal Molecular Imaging and X-ray Irradiator Module for Molecular Image Guided Radiation Therapy (MIGRT) in Preclinical Research

treatment. RISAD-P is not toxic at MBq/kg doses projected for clinical use. It has excellent prostate cancer targeting properties. Transient uptake of RISAD-P is observed in the genitourinary tract and stomach. When the KI blockade is omitted, some uptake of I, a catabolite of IRISAD-P, by the thyroid is also observed. The elimination half-life of IRISAD-P from prostate tumors is estimated at w102 h, resulting in the absorbed radiation doses of 260, 1,320, 180 rad mCi g for I-, I-, and IRISAD-P, respectively. Conclusions: Herein, we described a theranostic drug that targets AR, participates in DNA synthesis, and represents a unique approach for the detection and treatment of prostate cancer. RISAD-P is a promising candidate for imaging of the AR expression and tumor proliferation as well as molecular radiation therapy for metastatic or locally, regionally advanced prostate cancer. Author Disclosure: J.B. Kortylewicz: None. G. Han: None. T. Enke: None. E. Mack: None. C.A. Enke: None. K.A. Estes: None. R.L. Mosley: None. Z.P. Kortylewicz: None.